NovaBiotics is a leading clinical stage biotechnology company focused on the design and development of first-in-class anti-infective therapies for difficult to treat, poorly served infectious conditions. Our rational drug design approach and unique patented peptide anti-infective technology has already been validated through successful clinical development of the company's lead compound, Novexatin®, a topical (brush on) treatment for fungal nail infections. A robust and exciting pipeline of drug candidates are also being developed for conditions such as life threatening blood stream fungal infections (predominantly candidaemia) and cystic fibrosis.


| Home |
| About Us |
| Novexatin® |
| Novamycin® |
| Lynovex® |
| Novarifyn® |
| Pipeline |
| News and Press |
| Contract Research |
| Outreach |
| Contact Us |
Latest News
8th May 2013
16th January 2013
Lynovex® ex vivo study for cystic fibrosis
December 2012
Deborah O'Neil takes over as Editor of the European Biopharmaceutical review.
November 2012
Deborah O'Neil joins the Life Science Advisory Board for Scotland
September 2012
Dr. Deborah O'Neil joins the board of the Scottish Life Science Association
8th September 2012
11th June 2012
NovaBiotics presented at the 35th European Cystic Fibrosis Conference on the 6th - 9th June 2012
8th March 2012
14th February 2012
17th January 2012
22nd December 2011
NovaBiotics shall be attending the JP Morgan healthcare event from 9th to 12th January 2012
20th December 2011
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status
27th October 2011
NovaBiotics shall be attending BioEurope 2011 in Duesseldorf, Germany
17th October 2011
Lynovex® Orphan Drug Status
17th June 2011
NovaBiotics selected to present at BIO 2011
24th May 2011
NovaBiotics shall be attending BioDundee on the 8th & 9th June 2011
3rd May 2011
NovaBiotics featured in IMS Drug News
31st March 2011
NovaBiotics shall be attending BioTrinity 2011 from 12th - 14th April 2011
28th March 2011
NovaBiotics are attending the UK-Netherlands Joint Symposium on Antimicrobial Peptides in Durham, UK
21st February 2011
December 2010
NovaBiotics attending Peptide Formulation and Product Development Forum
November 2010
NovaBiotics Selected to present at Bio-Europe
September 2010
August 2010
NovaBiotics selected to present at ICAAC 2010
June 2010
NovaBiotic's Unblinded Phase IIa Novexatin® Data delivers excellent results
May 2010
NovaBiotics Successful Completion of Phase IIa clinical trial for Novexatin®